AFT-70 NAVIGATE will test whether Signatera-guided treatment can reduce unnecessary CDK4/6 inhibitor exposure while maintaining outcomes in more than 2,000 patients.
Key Investor Takeaways
- Natera (NASDAQ:NTRA) is collaborating on a global Phase III MRD-guided breast cancer trial using its Signatera Genome test.
- AFT-70 NAVIGATE is expected to enroll more than 2,000 patients across approximately 200 U.S. and international sites.
- The study will assess whether Signatera MRD monitoring can identify when CDK4/6 inhibitor therapy should be added rather than given upfront to all eligible patients.
- Signatera Genome offers analytical sensitivity below 1 part per million, according to the companies, supporting its role in detecting molecular residual disease.
- The primary endpoint is non-inferiority in four-year distant recurrence-free survival, making clinical outcomes central to validating the MRD-guided strategy.
Why NTRA Stock Is in Focus
Alliance Foundation Trials has launched AFT-70 NAVIGATE, a randomized Phase III study evaluating an MRD-guided treatment approach in patients with intermediate- and high-risk ER-positive/HER2-negative early breast cancer.
The trial is sponsored and led by AFT, with Natera and Genentech providing collaboration and co-funding. It combines Natera’s Signatera Genome MRD testing with giredestrant, Genentech’s investigational oral selective estrogen receptor degrader.
More than 2,000 stage II-III patients eligible for endocrine therapy are expected to participate at roughly 200 sites. Patients must have no detectable MRD by Signatera after completing standard-of-care treatment.
The control group will receive standard endocrine therapy alongside upfront CDK4/6 inhibition. Patients in the investigational group will receive giredestrant alone, with a CDK4/6 inhibitor introduced only if Signatera subsequently detects MRD.
The study will determine whether that selective approach is non-inferior based on four-year distant recurrence-free survival.
Why This Matters for Investors
For Natera, AFT-70 NAVIGATE places Signatera at the centre of a large Phase III trial in which MRD results are being used to guide treatment decisions rather than simply monitor disease.
That distinction may be important to the longer-term clinical positioning of Signatera. If the study demonstrates that MRD-guided monitoring can safely determine which patients require additional therapy, it could strengthen the case for using blood-based MRD testing as part of treatment-management strategies in early breast cancer.
The study also tests a potentially meaningful clinical proposition: whether patients can avoid prolonged CDK4/6 inhibitor exposure, including its associated side effects and monitoring burden, without compromising cancer outcomes.
However, the trial is designed to answer that question rather than establish that the approach already works. The significance for Natera therefore depends on eventual clinical results demonstrating that the MRD-guided strategy can meet the study’s non-inferiority endpoint.
Signatera’s selection also extends Natera’s clinical evidence programme in ER-positive/HER2-negative breast cancer. The company cited previous evidence from the AFT-05 PALLAS and MonarchE trials alongside the sub-1 ppm analytical sensitivity of its newer Signatera Genome technology.
What to Watch Next
Investors can watch enrollment progress across the planned international study network and subsequent updates on AFT-70 NAVIGATE.
The most important longer-term catalyst will be whether the investigational strategy achieves non-inferiority in four-year distant recurrence-free survival. That result will determine whether MRD-guided escalation can support the trial’s goal of reducing unnecessary CDK4/6 inhibitor treatment while maintaining clinical outcomes.